StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Alosetron

HCID 178944954
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
1190043-13-0
Standard-SMILES
Cc1nc[nH]c1CN1CCc2c(c3ccccc3n2C)C1=O
InChIKey
JSWZEAMFRNKZNL-UHFFFAOYSA-N
Summenformel
C17H18N4O
Durchschnittliche Molmasse
294,35 g/mol

Überblick

Alosetron is a pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position. It has a role as a serotonergic antagonist, an antiemetic and a gastrointestinal drug. It is a member of imidazoles and a pyridoindole.

Namen und Bezeichner

Bevorzugter Name
Alosetron
IUPAC
5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one
Englischer Name
Alosetron D3
Summenformel
C17H18N4O
Molmasse
294.36

Namen und Synonyme

alosetron122852-42-0GR68755GR 687555-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-oneA03AE01CHEBI:25334213Z9HTH1152,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-DTXSID60442785-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H,2H,3H,4H,5H-pyrido[4,3-b]indol-1-one
Weitere Namen anzeigen
Alosetron D32-[(5-methyl-1H-imidazol-4-yl)methyl]-5-(trideuteriomethyl)-3,4-dihydropyrido[4,3-b]indol-1-oneAlosetron D3Q: What is Alosetron D3 Q: What is the CAS Number of Alosetron D3 Q: What is the storage condition of Alosetron D3 Q: What are the applications of Alosetron D3
alosetron monohydrochloride2,3,4,5-Tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-onealosetronum5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H,2H,3H,4H,5H-pyrido(4,3-b)indol-1-one5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-3,4-dihydropyrido(4,3-b)indol-1-oneRefChem:58090DTXCID4024278Lotronex

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
1,6
Polarare Oberfläche (TPSA)
53,9 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
2
Schwere Atome
22
Formalladung
0
Komplexität
442

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LogP2
Solubility4.38e-01 g/L
Human DrugsBreast Feeding; Lactation; Gastrointestinal Agents; Serotonin Antagonists;
Physical DescriptionSolid

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Adverse Effects · 1 Eintrag

The most common adverse effect associated with alosetron administration is constipation. A randomized, double-blind, placebo-controlled study assessed the efficacy and safety of alosetron 0.5 mg and 1 mg in women with severe IBS-D. The study data revealed that constipation occurred in patients receiving 0.5 mg (9%), 1 mg once daily (16%), and 1 mg twice daily (19%).

Toxicity SummarySigns and Symptoms of Overdose
Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

alosetron

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein Binding82%
Pharmacodynamics · 1 Eintrag

Alosetron is a potent and selective antagonist of the serotonin 5-HT<sub>3</sub> receptor type. Activation of these receptors and the resulting neuronal depolarization affects the regulation of visceral pain, colonic transit, and GI secretions processes that are related to IBS. By blocking these receptors, alosetron is able to effectively control IBS.

Mechanism of Action · 1 Eintrag

Alosetron is a potent and selective 5-HT<sub>3</sub> receptor antagonist. 5-HT<sub>3</sub> receptors are nonselective cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of visceral pain, colonic transit and gastrointestinal secretions, processes that relate to the pathophysiology of irritable bowel syndrome (IBS). 5-HT<sub>3</sub> receptor antagonists such as alosetron inhibit activation of non-selective cation channels which results in the modulation of serotonin-sensitive GI motor and sensory processes.

Biological Half-Life1.5 hours
Metabolism/Metabolites · 2 Einträge

Hepatic, via microsomal cytochrome P450 (CYP)

Alosetron has known human metabolites that include 6-Hydroxy-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one and 6-hydroxy-5-methyl-2-[(5-methyl-2-oxo-1,3-dihydroimidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one.

FDA Pharmacological Classification · 6 Einträge

13Z9HTH115

ALOSETRON

Mechanisms of Action [MoA] - Serotonin 3 Receptor Antagonists

Established Pharmacologic Class [EPC] - Serotonin-3 Receptor Antagonist

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
1190043-13-0
ChEMBL
CHEMBL1110
ChEBI
CHEBI:253342
UNII
13Z9HTH115
Nikkaji
J532.750D

Alosetron is a Serotonin-3 Receptor Antagonist. The mechanism of action of alosetron is as a Serotonin 3 Receptor Antagonist.

ALOSETRON

MeSH Pharmacological Classification · 2 Einträge

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.

Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.

Absorption, Distribution and Excretion · 4 Einträge

50-60 %

Renal elimination of unchanged alosetron accounts for only 6% of the dose. Alosetron is extensively metabolized in humans.

65 to 95 L

600 mL/min

Cellular LocationsMembrane